GlassScriptPhysician profile
Daisy Lankarani
NPI 1881078467
$18,047.03
in general payments reported to CMS, 2019-2025
34 companies · $3,859 in 2025
The $3,859 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,716 · 2020: $13.15 · 2021: $782 · 2022: $3,851 · 2023: $3,766 · 2024: $4,060 · 2025: $3,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,489.42 |
| Education | $195.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,285.47 | 2021-2025 | |
| Janssen Biotech, INC. | $1,559.17 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Boston Scientific Corporation | $1,385.83 | 2019 | |
| Ardelyx, INC. | $964.95 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $838.57 | 2021-2024 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $757.31 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $653.09 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $651.72 | 2024-2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $633.20 | 2022-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $618.73 | 2022-2025 | |
| Pfizer INC. | $588.28 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $577.74 | 2021-2024 | Zeposia |
| Celgene Corporation | $537.70 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $521.01 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $371.08 | 2024-2025 | Omvoh, Zepbound |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $267.92 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $253.27 | 2019-2023 | Ocaliva |
| Amgen INC. | $242.29 | 2022-2023 | Avsola |
| Ipsen Biopharmaceuticals, INC | $230.13 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $184.15 | 2019-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $165.19 | 2022-2024 | Linzess |
| Celltrion USA INC. | $162.12 | 2024 | Zymfentra |
| Histosonics, INC. | $117.38 | 2024 | |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
| Redhill Biopharma INC. | $70.29 | 2022-2023 | Talicia |
| Lucid Diagnostics INC. | $64.80 | 2022-2023 | |
| Evoke Pharma, INC. | $49.51 | 2022-2023 | Gimoti |
| Echosens North America, INC. | $47.08 | 2025 | Fibroscan |
| Qol Medical, LLC | $39.66 | 2024-2025 | Sucraid, Sucraid |
| Endogastric Solutions, INC | $29.45 | 2024 | Esophyx |
| Shield Therapeutics INC | $25.28 | 2023 | Accrufer |
| Medtronic, INC. | $19.10 | 2023 | Gi Genius |
| Alnylam Pharmaceuticals INC. | $18.84 | 2022 | |
| Eisai INC. | $13.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Lankarani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.